Article Text

Download PDFPDF

IS-003 Early Inhaled Corticosteroids For The Prevention Of Bronchopulmonary Dysplasia In Extremely Preterm Infants: The Neonatal European Study Of Inhaled Steroids (neurosis)
  1. D Bassler1,
  2. V Carnielli2,
  3. HL Halliday3,
  4. M Hallman4,
  5. PH Jarreau5,
  6. R Plavka6,
  7. M Schwab7,
  8. ES Shinwell8,
  9. J van den Anker9,
  10. CF Poets10
  1. 1Neonatology, University Hospital Zurich, Zurich, Switzerland
  2. 2Paediatrics, Children’s Hospital Azienda Ospedaliero-Universitaria, Ancona, Italy
  3. 3Child Health, Royal Maternity Hospital, Belfast, UK
  4. 4Pediatrics and Adolescence and Neonatal Research Laboratory, Oulu University Hospital, Oulu, Finland
  5. 5Service de Médecine Néonatale de Port-Royal and Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France
  6. 6Pediatrics, General Faculty Hospital in Prague, Prague, Czech Republic
  7. 7Clinical Pharmacology University Hospital Tübingen, Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Tübingen, Germany
  8. 8Neonatology, Ziv Medical Center Bar-Ilan University, Tsfat, Israel
  9. 9Pediatrics, Children’s National Medical Center, Washington, USA
  10. 10Neonatology, University Children’s Hospital, Tübingen, Germany


Background Survival of extremely low birth weight (ELBW) infants has improved in recent decades but bronchopulmonary dysplasia (BPD) remains a major problem. The effect of early inhalation of corticosteroids on survival without BPD in these infants is unclear.

Objective To determine the effect of early use of inhaled budesonide in infants with gestational ages of 23 0/7–27 6/7 weeks requiring any form of positive pressure support on survival without BPD at 36 weeks’ gestational age.

Methods Randomised controlled trial. Budesonide or placebo were continued until infants were either off supplementary oxygen and positive pressure support or had reached a gestational age of 32 0/7 weeks regardless of their ventilator status. The primary outcome was death before 36 weeks of gestational age or survival with BPD, defined according to the physiological definition.

Results We randomly assigned 863 infants during the first 12 h of life in 40 centres in 9 countries to inhaled budesonide or placebo. In 7 infants consent was withdrawn. Of the 437 infants assigned to inhaled budesonide, 175 died or survived with BPD (40.0%), as compared with 194 of 419 infants assigned to placebo (46.3%). Further results are shown in the table.

Conclusions The reduction of the primary outcome (death before 36 weeks or BPD) by inhaled budesonide in ELBW infants was of borderline statistical significance. Inhaled budesonide significantly reduced BPD, which is a component of our primary outcome and was a predefined secondary outcome.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.